Aug 18, 2022 – View our latest newsletter honoring Dr. Judith K. Jones at ICPE + DGI’s Free & Discounted Offerings
Topics include:
- How Dr. Judith K. Jones will be honored at the upcoming 38th ICPE
- Special discount for new subscribers
- What have we been up to & what’s next at DGI?
Aug 11, 2022 – Our 20th Japanese profile has just been uploaded
The National Cancer Registry (NCR) commenced operations in January 2016. Accurate nationwide data obtained from NCR contribute to the planning and evaluation of cancer control in Japan. This database is utilized in evaluating the quality of medical care for cancer patients, in assessing the accuracy of cancer screening, and in follow-up surveys in nationwide cohort studies.
National Cancer Registry (Japan)
Database Contact Data
Please complete the contact form (in Japanese or English) at - https://reg18.smp.ne.jp/regist/is?SMPFORM=ndqe-lfogsa-3b8c6f3d580c85ee376b1c4fd94627fa
Alternate Contact
National Cancer Center of Japan can be contacted via the form on this page:
https://ganjoho.jp/med_pro/cancer_control/can_reg/national/datause/index.html
References of Studies Using/Describing Database
1. Nakata K, Matsuda T, Hori M, Sugiyama H, Tabuchi K, Miyashiro I, Matsumoto K, Yoneda A, Takita J, Shimizu C, Katanoda K. Cancer incidence and type of treatment hospital among children, adolescents, and young adults in Japan, 2016-2018. Cancer Sci. 2023 Sep;114(9):3770-3782.
2. Ogata D, Namikawa K, Nakano E, Fujimori M, Uchitomi Y, Higashi T, Yamazaki N, Kawai A. Epidemiology of skin cancer based on Japan's National Cancer Registry 2016-2017. Cancer Sci. 2023 Jul;114(7):2986-2992.
3. Matsumoto H, Kobayashi N, Shinoda S, Goto A, Kaneko A, Fukuda N, Kamimaki C, Kubo S, Watanabe K, Horita N, Hara Y, Ishikawa Y, Kaneko T. Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan. Sci Rep. 2023 Mar 30;13(1):5208.
4. Katanoda K, Ito H, Ito Y, Katayama K, Nishino Y, Tsutsui A, Togawa K, Tanaka H, Ohno Y, Nakaya T. [Geographic information in National Cancer Registry data: Overseas examples and challenges in Japan]. Nihon Koshu Eisei Zasshi. 2023 Mar 23;70(3):163-170. Japanese.
5. Kurisu K, Fujimori M, Harashima S, Akechi T, Matsuda T, Saika K, Yoshiuchi K, Miyashiro I, Uchitomi Y. Suicide, other externally caused injuries, and cardiovascular disease within 2 years after cancer diagnosis: A nationwide population-based study in Japan (J-SUPPORT 1902). Cancer Med. 2023 Feb;12(3):3442-3451.
6. Makiuchi T, Sobue T. Descriptive epidemiology of biliary tract cancer incidence and geographic variation in Japan. Eur J Cancer Prev. 2023 Jan 1;32(1):2-9.
7. Satake T, Morizane C, Rikitake R, Iwata S, Hirano H, Ogata D, Shimoi T, Sudo K, Yoshimoto S, Yamazaki N, Katoh Y. O12-2 The epidemiology of rare cancers from National Cancer Registry in Japan. Annals of Oncology. 2022 Jul 1;33:S473-4.
8. Kobayashi N, Oike T, Kubo N, Miyasaka Y, Mizukami T, Sato H, Adachi A, Katoh H, Kawamura H, Ohno T. Colorectal Cancer Screening Outcomes of 2412 Prostate Cancer Patients Considered for Carbon Ion Radiotherapy. Cancers (Basel). 2021 Sep 6;13(17):4481.
9. Okuyama A, Tsukada Y, Higashi T. Coverage of the hospital-based cancer registries and the designated cancer care hospitals in Japan. Jpn J Clin Oncol. 2021 May 28;51(6):992-998.
10. Yoshida M, Yabuuchi Y, Kakushima N, Kato M, Iguchi M, Yamamoto Y, Kanetaka K, Uraoka T, Fujishiro M, Sho M; Japan Duodenal Cancer Guideline Committee. The incidence of non-ampullary duodenal cancer in Japan: The first analysis of a national cancer registry. J Gastroenterol Hepatol. 2021 May;36(5):1216-1221.
July 5, 2022: The Swedish Multiple Sclerosis Registry profile has just been added
Active since 2001, the Swedish MS Registry (SMSreg) is a government-funded quality register designed to ensure optimal health care for patients with multiple sclerosis (MS). All Swedish neurology departments are users and providers of data, and currently more than 14,000 patients with MS have been registered.
Swedish Multiple Sclerosis Registry (Sweden) **
Database Contact Data
Prof. Jan Hillert
Karolinska University Hospital
17176 Stockholm
SWEDEN
Email: jan.hillert@ki.se
Alternate Contact
1. Anna Cunningham (Multiple Sclerosis)
Email: anna.cunningham@regionstockholm.se
2. Email - info@neuroreg.se
References of Studies Using/Describing Database
1. Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, Hambraeus J, Axelsson M, Nimer FA, Sundström P, Gunnarsson M, Johansson R, Mellergård J, Rosenstein I, Ayad A, Sjöblom I, Risedal A, de Flon P, Gilland E, Lindeberg J, Shawket F, Piehl F, Lycke J. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022 Aug;21(8):693-703.
2. Spelman T, Forsberg L, McKay K, Glaser A, Hillert J. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. Mult Scler. 2022 Jun;28(7):1051-1059.
3. Manouchehrinia A, Kingwell E, Zhu F, Tremlett H, Hillert J, Ramanujam R. A multiple sclerosis disease progression measure based on cumulative disability. Mult Scler. 2021 Oct;27(12):1875-1883.
4. Landtblom AM, Berntsson SG, Boström I, Iacobaeus E. Multiple sclerosis and COVID-19: The Swedish experience. Acta Neurol Scand. 2021 Sep;144(3):229-235.
5. Hedström AK, Hillert J, Brenner N, Butt J, Waterboer T, Strid P, Kockum I, Olsson T, Alfredsson L. DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies. J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):717-722.
6. Stenberg E, Forsberg L, Hedström A, Hillert J, Näslund E. Bariatric and metabolic surgery in patients with morbid obesity and multiple sclerosis - a nationwide, matched cohort study. Surg Obes Relat Dis. 2021 Jun;17(6):1108-1114.
7. Kågström S, Fält A, Berglund A, Piehl F, Olsson T, Lycke J. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance. Mult Scler Relat Disord. 2021 May;50:102842.
8. McKay KA, Friberg E, Razaz N, Alexanderson K, Hillert J. Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis. JAMA Neurol. 2021 Apr 1;78(4):478-482.
9. Hillert J, Magyari M, Soelberg Sørensen P, Butzkueven H, Van Der Welt A, Vukusic S, Trojano M, Iaffaldano P, Pellegrini F, Hyde R, Stawiarz L, Manouchehrinia A, Spelman T. Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Front Neurol. 2021 Mar 17;12:647811.
10. Alping P, Burman J, Lycke J, Frisell T, Piehl F. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology. 2021 Mar 16;96(11):e1574-e1584.